Free Trial 中
Wind ESG Rating

Access to ESG rating for China A-Shares and Hong Kong listed companies.

亚盛医药

6855.HK
Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司是一家主要从事血液系统恶性肿瘤治疗药物发现、研发及商业化的控股公司。公司主营业务是从事开发及销售针对肿瘤、乙肝及老化相关的疾病的新型小规模疗法。公司的主要产品包括Olverembatinib(HQP1351)、Lisaftoclax(APG-2575)、Alrizomadlin(APG-115)、Pelcitoclax(APG-1252)、APG-5918等产品。公司的产品主要用于治疗主要血液系统恶性肿瘤，包括慢性粒细胞白血病、急性粒细胞白血病、慢性淋巴细胞白血病、急性淋巴细胞白血病、骨髓增生异常综合症及多发性骨髓瘤。公司主要在国内市场开展业务。

ESG Score Industry Ranking:
10 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

Trend of Rating

2022-06-07: A; 2023-07-01: A; 2024-04-27: A; 2025-07-29: AA; 2026-08-06: AA A2022.06 A2023.07 A2024.04 AA2025.07 AA2026.08

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.11Updated on 2026-10-29
08.1110
Management & Practices Score：5.12Updated on 2026-10-08
05.127
Controversies Score：2.99Updated on 2026-10-29
02.993

ESG Score Comparison

Environmental Social Governance 亚盛医药生物科技Ⅲ Average
IndicatorCompany ScoreIndustry AverageWeight
Environmental7.213.6712.53%
Social7.734.5457.57%
Governance6.595.7829.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

  • 500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
  • 1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB
More Details

Peer Comparison(165 companies in the industry) ?

RankingCodeSecurity NameESG RatingESG ScoreControversies ScoreManagement & Practices ScoreEnvironmentalSocialGovernance
1603392.SH万泰生物AA8.862.965.907.578.548.58
2002252.SZ上海莱士AA8.682.995.697.758.128.29
31801.HK信达生物AA8.623.005.627.788.038.12
4300142.SZ沃森生物AA8.422.945.485.488.148.21
52269.HK药明生物AA8.283.005.288.457.477.29
61530.HK三生制药AA8.262.995.267.567.437.68
7920344.BJ三元基因AA8.162.965.204.337.977.69
7300122.SZ智飞生物AA8.162.975.195.407.428.24
96660.HK艾美疫苗AA8.123.005.126.397.377.57
106855.HK亚盛医药AA8.112.995.127.217.736.59